澳大利亚新州上诉法院驳回Cosette终止收购Mayne Pharma请求 6.72亿澳元交易纠纷再审结
据路透社10月14日报道，澳大利亚新南威尔士州上诉法院周三驳回美国制药企业Cosette Pharmaceuticals终止收购Mayne Pharma的请求，维持此前裁决，认定Cosette没有正当理由放弃这笔交易。
Cosette去年2月以每股7.40澳元出价收购Mayne，其后以Mayne财务表现恶化构成协议项下的“重大不利变化”为由试图退出。法院认定，Mayne销售表现的下滑未达到重大不利变化的门槛，评估盈利影响时须计入该公司实现的成本节约；法院同时驳回了Cosette关于Mayne在2025年盈利预期上误导其的说法，并判令Cosette支付上诉的诉讼费用。
这笔收购估值6.72亿澳元（约合4.697亿美元）。报道称，联邦财政部长吉姆·查默斯去年11月以国家利益为由阻止了该交易；Mayne Pharma周三早间一度停牌等待裁决。
Australian Court Dismisses Cosette Appeal to Drop Mayne Pharma Takeover
Reuters reported on October 14 that Australia's New South Wales Court of Appeal on Wednesday rejected Cosette Pharmaceuticals' bid to terminate its takeover of Mayne Pharma, upholding an earlier ruling that the US-based drugmaker had no valid grounds to abandon the deal.
Cosette bid A$7.40 per share for Mayne in February last year but later tried to back out, saying a deterioration in Mayne's financial performance constituted a material adverse change under the scheme implementation deed. The court found the decline in Mayne's sales performance was insufficient to meet that threshold, said cost savings made by the ASX-listed firm had to be taken into account when assessing the earnings impact, rejected Cosette's claim that Mayne had misled it over expected 2025 earnings, and ordered Cosette to pay the legal costs of the appeal.
The takeover is valued at A$672 million ($469.7 million). Federal Treasurer Jim Chalmers blocked the deal in November last year on national interest grounds, and Mayne Pharma entered a trading halt earlier on Wednesday pending the decision.
图片来源：位于悉尼的新南威尔士州最高法院建筑实景。图片来源：Wikimedia Commons，Sardaka 摄，CC BY-SA 4.0 授权
